

1. Record Nr.	UNINA9910677499803321
Titolo	Advances in Novel Formulations for Drug Delivery // edited by Raj K. Keservani, Rajesh Kumar Kesharwani, and Anil K. Sharma
Pubbl/distr/stampa	Hoboken, NJ ; ; Beverly, MA : , : John Wiley & Sons, Inc. : , : Scrivener Publishing LLC, , [2023] ©2023
ISBN	1-394-16770-9 1-394-16769-5
Descrizione fisica	1 online resource (576 pages)
Disciplina	615.6
Soggetti	Drug delivery systems
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Cover -- Title Page -- Copyright Page -- Contents -- Preface -- Part I: Novel Drug Carriers and Therapeutics -- Chapter 1 Nanoarchitected Materials: Their Applications and Present Scenarios in Drug Delivery -- 1.1 Introduction -- 1.2 Liposomes -- 1.3 Nanoparticles -- 1.3.1 Nanoparticles in Drug Delivery -- 1.4 Nanoemulsions -- 1.4.1 Advantages and Shortcomings of Nanoemulsions -- 1.4.2 Application of Nanoemulsion in Drug Delivery -- 1.5 Dendrimers -- 1.5.1 Synthesis of Dendrimers -- 1.5.2 Advantages of Dendrimers -- 1.5.3 Applications of Dendrimers in Drug Delivery -- 1.6 Aquasomes -- 1.6.1 Properties of Aquasomes -- 1.6.2 Application of Aquasomes in Drug Delivery -- 1.7 Nanogel -- 1.7.1 Properties of Nanogels -- 1.7.2 Nanogels in Drug Delivery -- 1.8 Quantum Dots -- 1.8.1 Applications of Quantum Dots in Drug Delivery -- 1.9 Carbon Nanotubes -- 1.9.1 Features of Carbon Nanotubes -- 1.9.2 Carbon Nanotubes in Drug Delivery -- References -- Chapter 2 Nanopharmaceuticals for Drug Delivery -- 2.1 Introduction -- 2.2 What Are Nanopharmaceuticals and What Do They Do? -- 2.3 Nanopharmaceuticals Importance -- 2.4 Nanotechnology -- 2.5 Pharmaceutical Companies and Nanotechnology -- 2.6 Applications and Advantages of Nanopharmaceuticals as Drug Carriers -- 2.7 Characteristics of Nanoparticles in Nanopharmaceuticals -- 2.7.1 Particle Size -- 2.7.2 Surface Properties of Nanoparticles --

2.7.3 Drug Loading -- 2.7.4 Drug Release -- 2.8 Targeted Drug Delivery -- 2.9 Types of Nanoparticles -- 2.10 Nanoparticle Preparation Methods -- 2.11 Evaluation of Nanoparticles -- 2.12 Efficiency of Drug Entrapment -- 2.13 Particle Shape -- 2.14 Size of the Particles -- 2.15 Zeta Potential -- 2.16 Rise of Nanopharmaceuticals -- 2.17 Nanopharmaceuticals Approval Regulations (FDA Rules & Regulations) -- 2.18 Conclusions and Prospects for the Future -- References.

Chapter 3 Applications and Prospects of Nanopharmaceuticals Delivery

-- 3.1 Introduction -- 3.2 Nanopharmaceuticals -- 3.3 Development of Nanopharmaceuticals -- 3.3.1 From Lab to the Marketplace -- 3.3.2 Techniques -- 3.3.3 Cost -- 3.3.4 Ethics -- 3.3.5 Nanopharmaceuticals Approval Regulations (FDA Rules & Regulations) -- 3.4 Clinical Applications of Nanotechnology -- 3.4.1 Diagnostic Applications -- 3.4.1.1 Detection -- 3.4.1.2 Protein Chips -- 3.4.1.3 Individual Target Probes -- 3.4.1.4 Nanotechnology as a Tool in Imaging -- 3.4.1.5 Sparse Cell Detection -- 3.4.2 Therapeutic Applications -- 3.4.2.1 Surfaces -- 3.4.2.2 Gene Delivery -- 3.4.2.3 Drug Delivery -- 3.4.2.4 Liposomes -- 3.4.2.5 Nanotechnology in Orthopedic Applications -- 3.4.2.6 Nanotechnology in Cardiac Therapy -- 3.4.2.7 Nanotechnology in Dental Care -- 3.4.2.8 Biomolecular Engineering -- 3.4.2.9 Biopharmaceuticals -- 3.5 Nanopharmaceuticals Delivery-Recent Applications -- 3.5.1 Nanoparticulate Systems for Vaccine -- 3.5.1.1 Polyanhydride-Based NPs -- 3.5.1.2 Biodegradable Synthetic PLGA NPs -- 3.5.1.3 Liposome-Based NPs -- 3.5.1.4 Polysaccharide-Based NPs -- 3.5.2 Chemotherapy -- 3.5.2.1 Increasing the Concentration of Chemotherapeutic Agents in Tumor Tissue -- 3.5.3 Drug/Gene Delivery -- 3.5.3.1 Nanoparticles Used in Drug Delivery System -- 3.5.3.2 Cellulose -- 3.6 Nanotechnology in Neurodegenerative Disorders Treatment -- 3.7 Future Perspective -- 3.8 Issues with Current Nanopharmaceutical Concepts -- 3.8.1 Large-Scale Manufacturing -- 3.8.2 Biological Challenges -- 3.8.3 Intellectual Property (IP) -- 3.8.4 Biocompatibility and Safety -- 3.8.5 Government Regulations -- 3.9 Conclusion -- References -- Chapter 4

Nanomedicine Regulation and Future Prospects -- 4.1 Introduction -- 4.2 Importance of Regulation of Nanomedicine.

4.3 Regulatory Challenges Faced by Nanomaterial in Medicine -- 4.3.1 Performing Various Functions -- 4.3.2 Nanomedicine Classification Issues -- 4.3.3 Variation in Size of the Particle -- 4.3.4 Manufacturing Process -- 4.3.5 Difficulties to Create CQA -- 4.3.6 Nanotoxicology and Cellular Response -- 4.3.7 Administering Right Doses -- 4.3.8 Pharmacokinetics -- 4.3.9 Developing Guidelines -- 4.4 Nanomedicine Future Aspects -- 4.5 Challenges that Threaten the Future of Nanomedicine -- 4.5.1 Financial Crisis -- 4.5.2 Lack of Confidence -- 4.5.3 Potential Dangers -- 4.5.4 Unsuccessful Patenting -- 4.5.5 Breakdowns in the Pharmaceuticals and Financial Markets -- 4.5.6 Limited Regulation -- 4.6 Future Prospects for Nanomedicine -- 4.6.1 Emerging Nanomaterials -- 4.6.2 Personalized Nanomedicine -- 4.6.3 Nanorobots and Nanodevices -- 4.6.4 Orthopedic Augmentations and Cytocompatibility -- 4.6.5 Cardiology and Nanotechnology -- 4.6.6 Cancer and Nanotechnology -- 4.6.7 NAPT -- 4.6.8 Gene, Protein, Lab-on-a-Chip Devices -- 4.6.9 Polymeric Nanoparticles in Medicine -- References -- Chapter 5 Nanotechnology Application in Drug Delivery for Medicinal Plants -- 5.1 Introduction -- 5.1.1 Nanodrug Delivery Systems (NDDS) -- 5.2 Nanoherbals -- 5.2.1 *Cucuma longa* (Cucurmin) -- 5.2.2 *Gingko biloba* -- 5.2.3 *Artemisia* -- 5.2.4 *Silybum marianum*-Silymarin -- 5.2.5 *Salvia miltiorrhiza* (Danshen) -- 5.2.6 *Glycyrrhiza glabra* (L.) -- 5.2.7 *Camellia sinensis* (Green tea) -- 5.2.8 *Camptotheca*

acuminata -- 5.2.9 *Leea indica* -- 5.2.10 *Ziziphus mauritiana* (Malay apple) -- 5.2.11 *Cuscuta chinensis* -- 5.3 Conclusion -- References -- Chapter 6 Nanosystems Trends in Nutraceutical Delivery -- 6.1 Introduction -- 6.2 Classification of Nutraceuticals -- 6.3 Biopharmaceutical Issues Associated with Nutraceuticals -- 6.4 Nanosystems for Delivery of Nutraceuticals -- 6.4.1 Nanoemulsions. 6.4.2 Self-Emulsifying Systems -- 6.4.3 Solid Lipid Nanoparticles and Nanostructured Lipid Carriers -- 6.4.4 Liposomes -- 6.4.5 Polymeric Nanoparticles -- 6.4.6 Inorganic Nanoparticles -- 6.5 Challenges -- 6.6 Market Potential -- 6.7 Conclusion and Perspective -- References -- Chapter 7 Nanoencapsulated Systems for Delivery of Phytopharmaceuticals -- 7.1 Introduction -- 7.1.1 Nanoencapsulation Techniques in Phytopharmaceuticals -- 7.1.1.1 Physical-Chemical Techniques -- 7.1.1.2 Chemicals Techniques -- 7.1.1.3 Mechanical Techniques -- 7.1.2 Characterization of Nanoencapsulates -- 7.1.2.1 Morphological Characterization -- 7.1.2.2 Physicochemical Characterization -- 7.1.3 Nanoencapsulated Systems for Free Delivery of Phytopharmaceuticals -- 7.1.4 Studies to Evaluate Phytopharmaceuticals Nanoencapsulates -- 7.2 Conclusions -- References -- Chapter 8 Topical Drug Delivery Using Liposomes and Liquid Crystalline Phases for Skin Cancer Therapy -- 8.1 Introduction -- 8.2 Liposomes for Topical Application -- 8.2.1 Development of Liposomal Nanoparticles -- 8.3 Liquid Crystals and Liquid Crystalline Nanodispersions for Topical Application -- 8.3.1 Characterization Techniques -- 8.4 Physical Methods Applied to Nanoparticles Delivery -- 8.4.1 Sonophoresis -- 8.4.2 Microneedles -- 8.5 Conclusions and Perspectives -- Acknowledgements -- References -- Chapter 9 Vesicular Drug Delivery in Arthritis Treatment -- 9.1 Introduction -- 9.2 Skin Penetration Pathways -- 9.2.1 Intercellular Pathway -- 9.2.2 Transcellular Pathway -- 9.2.3 Appendgeal Pathway -- 9.3 Principles of Drug Permeation Through Skin -- 9.4 Problems Associated with Conventional Dosage Forms -- 9.5 Novel Treatment Strategies for Arthritis -- 9.5.1 Traditional Liposomes as Skin Drug Delivery Systems -- 9.5.2 Transfersomes (Ultradeformable Liposomes) as Skin Drug Delivery Systems. 9.5.3 Ethosomes as Skin Drug Delivery Systems -- 9.5.4 Niosomes as Skin Drug Delivery Systems -- 9.6 Conclusion and Future Perspectives -- References -- Chapter 10 Perspectives of Novel Drug Delivery in Mycoses -- 10.1 Introduction -- 10.2 Role of Conventional Drugs in Antifungal Therapy -- 10.3 Mechanism of Action of Conventional Antifungals -- 10.4 Summary of Nanoparticles and Their Role in Antifungal Therapy -- 10.4.1 Lipid Nanoparticles -- 10.4.2 Liposome -- 10.4.3 Transfersomes -- 10.4.4 Transethosomes -- 10.4.5 Solid Lipid Nanoparticles (SLN) -- 10.4.6 Nanostructured Lipid Carriers (NLC) -- 10.4.7 Polymer Lipid Hybrid Nanoparticles (PLN) -- 10.4.8 Polymeric Nanoparticles -- 10.4.9 Microsponge and Nanosponge Systems -- 10.4.10 Polymeric Micelles -- 10.4.11 Polymersomes -- 10.4.12 Dendrimers -- 10.4.13 Metallic Nanoparticles -- 10.5 Other Drug Delivery Systems -- 10.5.1 Niosomes -- 10.5.2 Spanlastics -- 10.5.3 Microemulsions and Nanoemulsions -- 10.5.4 Silicon Dioxide Nanoparticles -- 10.6 Conclusion -- References -- Chapter 11 Nano-Based Drug Delivery in Eliminating Tuberculosis -- 11.1 Introduction -- 11.1.1 Latent and Active Tuberculosis -- 11.1.2 Multidrug-Resistant Tuberculosis (MDR-TB) -- 11.1.3 Extensively Drug-Resistant TB -- 11.2 Antitubercular Therapy -- 11.3 Therapies Based on Nanotechnology -- 11.3.1 Nanoparticles for Anti-TB Therapy -- 11.3.2 Advantages and Disadvantages of Nanoparticles -- 11.3.3 Types of Nanoparticles and Their Characteristics -- 11.3.3.1 TB Dendrimers --

11.3.3.2 Cyclodextrins -- 11.3.3.3 Polymeric Micelles -- 11.3.3.4
Liposomes -- 11.3.3.5 Nanoemulsions -- 11.3.3.6 Solid Lipid
Nanoparticles -- 11.3.3.7 Niosomes -- 11.3.3.8 Polymeric
Nanoparticles -- 11.4 Routes of Administration of Nanoparticles --
11.4.1 Oral Administration of Nanoparticles -- 11.4.2 Inhalational
Administration of Nanoparticles.
11.4.3 Intravenous Administration of Nanoparticles.
